Hopital Femme Mere Enfant Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2011
NCT01370798
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

HOPITAL FEMME MERE ENFANT CHU DE LYON | Hopital Femme Mere Enfant, Hospices Civils de Lyon | Hopital Femme Mère Enfant, l'Escale MPR pédiatrique (Hospices Civils de Lyon). Bron, France | Hopital Femme-Mere-Enfant Service D'Epilepsie -5eme etage 59 Boulevard Pinel Bron, France

Active Ingredients

Drugs in Phase 3 Trials (4)

promestriene (1 trial)

rufinamide (banzel) (1 trial)

vedrop (1 trial)

vitamin e (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypobetalipoproteinemias (Phase 3)

Hypospadias (Phase 3)

Lennox Gastaut Syndrome (Phase 3)

Postoperative Complications (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4